Amphiregulin as a driver of tissue fibrosis.
Most deaths in Western countries can currently be associated with fibrotic diseases. During fibrosis excessive amounts of extra-cellular matrix components, such as collagen, are deposited in tissues, which can lead to tissue stiffness and organ failure. The underlying mechanisms leading to tissue fibrosis remain poorly understand and, consequently, our capacities to treat fibrotic diseases remain limited. Currently approved drugs only delay the progression of fibrosis and are often associated with severe side-effects, which limit their clinical application. Thus, a better understanding of the ontology of fibrotic diseases and the development of more specific and more efficient drugs for the treatment of tissue fibrosis is an urgent clinical meet.